LPS-Induced Galectin-3 Oligomerization Results in Enhancement of Neutrophil Activation

Marise Lopes Fermino1,2, Claudia Danella Polli1,3, Karina Alves Toledo1,2,4, Fu-Tong Liu6, Dan K. Hsu6, Maria Cristina Roque-Barreira2, Gabriela Pereira-da-Silva5, Emerson Soares Bernardes7,**, Lise Halbwachs-Mecarelli1,2,*

1 Université Paris Descartes, Sorbonne Paris Cité, Paris, France, 2 Department of Cellular and Molecular Biology and Pathogenic Bioagents, Faculty of Medicine, University of São Paulo, Ribeirão Preto, São Paulo, Brazil, 3 Program of Basic and Applied Immunology, Faculty of Medicine, University of São Paulo, Ribeirão Preto, São Paulo, Brazil, 4 Department of Biologic Sciences, University of São Paulo, São Paulo, Brazil, 5 Ribeirão Preto College of Nursing, University of São Paulo, Ribeirão Preto, São Paulo, Brazil, 6 Department of Dermatology, School of Medicine, University of California Davis, Sacramento, California, United States of America, 7 Institute of Molecular Pathology and Immunology, University of Porto, Porto, Portugal

Abstract
Galectin-3 (Gal 3) is a glycan-binding protein that can be secreted by activated macrophages and mast cells at inflammation sites and plays an important role in inflammatory diseases caused by Bacteria and their products, such as lipopolysaccharides (LPS). Although it is well established that Gal 3 can interact with LPS, the pathophysiological importance of LPS/Gal 3 interactions is not fully understood. Data presented herein demonstrate for the first time that the interaction of Gal 3, either via its carbohydrate binding C-terminal domain or via its N-terminal part, with LPS from different bacterial strains, enhances the LPS-mediated neutrophil activation in vitro. Gal 3 allowed low LPS concentrations (1 µg/mL without serum, 1 ng/mL with serum) to upregulate CD11b expression and reactive oxygen species (ROS) generation on human neutrophils in vitro and drastically enhanced the binding efficiency of LPS to the neutrophil surface. These effects required LPS preincubation with Gal 3, before neutrophil stimulation and involved specific Gal 3/LPS interaction. A C-terminal Gal-3 fragment, which retains the lectin domain but lacks the N-terminal part, was still able to bind both to *Escherichia coli* LPS and to neutrophils, but had lost the ability to enhance neutrophil response to LPS. This result emphasizes the importance of an N-terminus-mediated Gal 3 oligomerization induced by its interaction with LPS. Finally we demonstrated that Balb/C mice were more susceptible to LPS-mediated shock when LPS was pretreated with Gal 3. Altogether, these results suggest that multimeric interactions between Gal 3 oligomers and LPS potentiate its pro-inflammatory effects on neutrophils.

Introduction
Lipopolysaccharide (LPS) represents a major pathogen-associated molecular pattern (PAMP) from the outer membrane of Gram-negative bacteria and is a potent immune activator closely associated with many infectious and inflammatory diseases [1,2]. LPS recognition by polymorphonuclear neutrophils is one of the first steps of innate immunity. Neutrophil activation by LPS involves both the GPI-anchored molecule CD14 and the Toll-like receptor-4 (TLR-4), with occasional participation of TLR-2 binding to lipoproteins. This activation results in neutrophil degranulation and the activation of the oxidative burst [3]. Since LPS is a powerful immune activator and may be fatal, the response to LPS must be tightly regulated to maintain the immune response at an appropriate level [4].

Gal 3 is a glycan-binding protein composed of a single carbohydrate-recognition domain (CRD) [5–7] and an N-terminal aggregation part responsible for its ability to form oligomers, mainly pentamers [8–10]. It is widely distributed in tissues, and is predominately expressed by innate cells, including mast cells, neutrophils and eosinophils [11]. Gal 3 is up-regulated during inflammation/infection, and *in vivo* experiments using Gal 3-deficient mice emphasized the critical role of this protein in regulating inflammatory responses [12–15]. Several reports have described the binding of Gal 3 to neutrophil surface and the regulation of neutrophil functions by this protein [16–20]. However, the roles of Gal 3 remain unclear, since Gal 3 was claimed either to favour neutrophil recruitment and activation [12–15] or to down-regulate the LPS-induced inflammatory responses [21]. One should point out that Gal 3 ubiquitous subcellular distribution and its multiple extracellular and intracellular biological effects render difficult the interpretation of phenotypes observed with Gal 3−/− mice. Our aim was to clarify the modulation by Gal 3 of LPS-mediated neutrophil activation...
and to investigate Gal 3 mechanisms of action. Data presented herein demonstrate that exogenous Gal 3 lowers the activation threshold of LPS-stimulated neutrophils by interacting directly with LPS and by enhancing its ability to bind neutrophils. Furthermore, the complex formed between LPS and Gal 3 modifies LPS structure, as deduced from fluorescence dequenching and decreases mice resistance to the lethal effects of LPS.

**Methods**

**Reagents**

Hanks’ balanced salt solution with or without Ca\(^{2+}\) and Mg\(^{2+}\) (HBSS\(^{+}\)) was purchased from Gibco (Paisley, Scotland) and Polymorphprep from Nycomed (Oslo, Norway). LPS from *Escherichia coli* O55:B5, *Escherichia coli* fluorescent isothiocyanate (FITC)-conjugated LPS (FITC-LPS), lactose, sucrose, and formyl-Met-Leu-Phe-OH (fMLP) were obtained from Sigma-Aldrich (St. Louis, MO), while LPS from *Salmonella Minnesota* R7 was kindly donated by Dr. Catherine Fitting (Pasteur Institute, Paris, FR). LPS preparations were sonicated to prepare homogeneous solutions. Recombinant human tumor necrosis factor alpha (TNF-\(\alpha\)) and interleukin-8 (IL-8) were from PeproTech (Rocky Hill, NJ). Desalting Columns from Thermo Scientific (MA, USA), Detoxi-Gel\textsuperscript{TM} from (IL-8) were from PeproTech (Rocky Hill, NJ). Desalting Columns from Thermo Scientific (MA, USA), Detoxi-Gel\textsuperscript{TM} from Pierce (Rockford, IL), anti-CD11b (FITC), -CD14 (FITC), -TLR4 (biotin) monoclonal antibodies, Streptavidin-PE, and control isotypes were from AbD Serotec (Düsseldorf, Germany). The polyclonal anti-Gal 3 antibody was produced as previously described [10].

**Galectin-3 preparation**

Recombinant human Gal 3 was produced in *Escherichia coli* and purified by as previously described [22]. The lectin was stored at 4°C in phosphate-buffered saline (PBS; pH 7.2) containing 150 mM lactose. Prior to use, lactose was removed by gel-filtration chromatography on desalting columns and galectin 3 was further purified by affinity chromatography on detoxi-gel beads to eliminate contaminating LPS. The carbosyl-terminal domain fragment of Gal 3 (Gal 3C) was prepared by digesting recombinant lectin with collagenase as described [22]. Labeling of Gal 3 with fluorescein isothiocyanate (FITC) was performed essentially as previously described [23].

**Neutrophil preparation**

Neutrophils were prepared at room temperature from EDTA-anticoagulated blood obtained at the French Blood Transfusion Center Établissement Français du Sang, with agreement for studies on healthy volunteers. An initial centrifugation for 20 minutes at 120 g allowed to recover the platelet-rich plasma, which was further centrifuged separately 10 minutes at 1000 g to remove platelets. Blood cells were resuspended in the platelet-poor plasma and neutrophils isolated by one step density-gradient centrifugation on Polymorphprep according to the manufacturer’s instructions. Residual erythrocytes were lysed in 0.2% NaCl for 1 minute and the osmolarity of the medium then equilibrated by the addition of an equal volume of 1.6% NaCl. Cells were washed in PBS and resuspended in HBSS\(^{+}\) to a final concentration of 2×10\(^6\) cells/mL.

**Neutrophil activation and flow cytometry**

Neutrophils (5×10\(^5\) in 250 µl of HBSS\(^{+}\), in 1% BSA-coated tubes, were incubated for 20–45 minutes at 37°C with the indicated molar concentration of Gal 3, LPS, 10 \(^{-8}\) M fMLP, 25 ng/mL IL-8, 10 ng/mL TNF-\(\alpha\) or only HBSS\(^{+}\). Alternatively, neutrophils were stimulated with a mixture containing Gal 3 and LPS. In this case, Gal 3 and LPS were preincubated together at concentrations at least 5 times higher than that used to stimulate neutrophils. After 20 min at 37°C, the Gal 3/LPS mixture was diluted with HBSS\(^{+}\), adjusted to indicated final concentrations and added to the neutrophil pellets. Resuspended neutrophils were then incubated at 37°C for 30 min. For sugar inhibition assays, Gal 3 was pre-incubated with 20 mM lactose or sucrose 15 minutes before use. To evaluate Gal 3 effects on LPS-mediated neutrophil activation in the presence of the LPS binding protein (LBP), 0.2% autologous serum was added to each stimulus condition. For flow cytometry analysis, following the activation, cells were washed with ice-cold PBS, 1% BSA, 0.1% sodium azide (PAA buffer) and incubated for 20 minutes with heat-aggregated goat IgG (1 mg/mL) to block Fcγ receptors, at 4°C, the low temperature and the presence of sodium azide preventing FcγR redistribution and activation. Cells were then treated at 4°C with FITC-labeled anti-CD11b, anti-CD14, or anti-TLR4 mAbs or a control FITC-labeled mouse IgG1 and analyzed by flow cytometry on a Becton Dickinson FACScalibur (Mountainview, CA).

**Reactive oxygen species generation**

PMN (1×10\(^6\)/ml in HBSS\(^{+}\)) were incubated with the fluorescent probe 2′,7′-dichlorofluorescent hydrodiacetate DCFHDA (5 µM) (Sigma-Aldrich) in BSA-coated tubes at 37°C for 30 min in the dark, with Gal 3 or LPS then with MLEP 10\(^{-6}\) M for 7 minutes. The reaction was stopped with ice-cold PBS-azide 0.1%. After centrifugation, the oxidation-dependent fluorescence of intracellular DCFHDA was measured by flow cytometry.

**LPS and galectin-3 binding assay**

A flow cytometric assay was developed to assess the effect of Gal 3 on the level of LPS binding on neutrophils. Cells (1×10\(^6\)) in 50 µl of HBSS\(^{+}\) were stimulated with 20 min at 37°C with FITC-labeled *Escherichia coli* LPS (12.5 µg/mL), which had been preincubated with different concentration of Gal 3 (from 0 to 8 µM) or with 4 µM of the truncated form of Gal 3 (Gal 3C). For sugar inhibition assays, lactose or sucrose (12.5 mM) were added to Gal 3, 15 minutes before use. For Gal 3 binding assay, non-activated neutrophils were washed with iced-PBA buffer and treated with 0.2 µM FITC-labeled Gal 3 in presence or absence of 10 mM lactose or sucrose. Following incubations, cells were washed with PBS and the binding of Gal 3 or LPS was measured by flow cytometry.

**Competition assay**

Each well in Microtiter plates with U-wells (Nunc, Roskilde, Denmark) was treated with 1 µg of recombinant Gal 3 overnight at 4°C. Plates were rinsed once with PBS, and the unbound protein binding sites in the wells were blocked with 3% (w/v) gelatin in PBS for 2 h at room temperature, followed by three PBS rinses. To each well was added 0.2 µM biotin-labeled Gal 3 and a fourfold concentration of unlabeled Gal 3 prepared in 1% gelatin, in presence or absence of 5 µg/ml *E.coli* LPS. Plates were incubated for 2 h at 37°C on an orbital shaker and washed with PBS five times. Following incubation with streptavidin-peroxidase for 1 h at 37°C, the Sigma FAST \(\alpha\)-phenylenediamine dihydrochloride (OPD) substrate was used for development of peroxidase reaction and the optical density was measured at 450 nm.

**FITC-LPS gel filtration and fluorescence analysis**

To study the effects of Gal 3 on LPS aggregate structure, 5 µg of FITC-LPS diluted in 200 µL PBS was incubated with 20 µM of Gal 3 or 2% human serum for 2 hours at 37°C. After incubation,
the mixture was loaded onto a Superdex TM 75 HR 10/30 column (Pharmacia, Uppsala, Sweden), running at a flow of 1 mL/min in PBS. FITC-LPS, Gal 3 or 2% serum alone were also analyzed. Samples were collected into 500 μL fractions and applied in a white 96-wells flat-bottom microtiter plate (Nunc, Roskilde, Denmark), and thereafter the fluorescence was measured in a Varioskan Flash Microplate Fluorescence reader (Thermo Scientific, Vantaa, Finland). The excitation and emission wavelengths were 475 nm and 520 nm, respectively.

Mouse model of endotoxin-mediated mortality

Female Balb/C mice, in groups of five, were challenged with E. coli LPS in three different doses (6.2, 12.5 and 25 mg/Kg) diluted in 0.5 mL of PBS, by intraperitoneal (IP) inoculation. Mice were observed for survival for 30 h. Using our established LD50 (Lethal Dose, 50%) of LPS, the effect of Gal 3 on LPS-induced mortality was assessed by preincubating Gal 3 (40 μM) and LPS (6.2 mg/Kg) in 0.5 mL of PBS for 30 min before IP administration. Control animals received PBS, Gal 3 only or LPS only. The Ethics Committee on Animal Research of the University of Sao Paulo approved all the procedures performed in the study described here.

Statistical Analysis

The results are expressed as the mean ±SD of the indicated number of animals or experiments. Statistical analysis was performed using analysis of variance followed by the parametric Tukey-Kramer test (Prism 5 GraphPad software, La Jolla, CA, USA). Log rank (Mantel-Cox) test was used to compare the survival rates between the study groups and generate the P value. Differences were considered statistically significant when p≤0.05.

Results

Recombinant galectin 3 exerts LPS-dependent and LPS-independent effects on human neutrophils

We first analyzed the effects of recombinant Gal 3, isolated from transfected E. coli as described [22], without (Gal 3 extract) and with (detoxi) LPS elimination on detoxi-gel and incubated with freshly isolated unprimed neutrophils. As shown in figure 1A, the incubation with 0.2 μM Gal 3 extract resulted in neutrophil activation, as measured by the increase of CD11b expression. This effect was not observed with the same molar concentration of endotoxin-free detoxigal-treated Gal 3 (detoxi-Gal 3). LPS contamination of the Gal 3 extract preparation, as measured by Limulus Amebocyte Lysate test (Limulus Amebocyte Lysate assay, La Jolla, CA, USA), was assessed by preincubating Gal 3 (40 μM) and LPS (6.2 mg/Kg) in 0.5 mL of PBS for 30 min before IP administration. Control animals received PBS, Gal 3 only or LPS only. The Ethics Committee on Animal Research of the University of Sao Paulo approved all the procedures performed in the study described here.

Figure 1. Contaminating LPS interferes with the ability of Gal 3 to activate neutrophils. Freshly isolated neutrophils (2.0×10⁶/ml) were incubated for 45 min at 37°C in HBSS++ in the presence of: A: Recombinant Gal 3 preparation (0.2 μM), which had been depleted of endotoxin (detoxi) or not (extract), by absorption on detoxigel (n = 3). B: 0.2 μM of extract or endotoxin-depleted recombinant Gal 3, which had been preincubated for 30 min at 37°C with polymyxin B (PMX, 40 mg/ml) (n = 3). C: Increasing molar concentrations of endotoxin-depleted Gal 3 (n = 3). After staining with a specific anti-CD11b mAb, cells were analyzed by flow cytometry. D: Non-stimulated PMN (2.0×10⁶/ml) were incubated with FITC-labeled Gal 3 (0.2 μM) for 30 min at 4°C, in the presence or absence of 20 mM sucrose or lactose. The binding of FITC-Gal 3 to neutrophils was analyzed by flow cytometry (n = 3). Results are expressed as mean fluorescence intensity (MFI). * p<0.05; **p<0.01; ***p<0.001. doi:10.1371/journal.pone.0026004.g001

Recombinant galectin 3 exerts LPS-dependent and LPS-independent effects on human neutrophils

We first analyzed the effects of recombinant Gal 3, isolated from transfected E. coli as described [22], without (Gal 3 extract) and with (detoxi) LPS elimination on detoxi-gel and incubated with freshly isolated unprimed neutrophils. As shown in figure 1A, the incubation with 0.2 μM Gal 3 extract resulted in neutrophil activation, as measured by the increase of CD11b expression. This effect was not observed with the same molar concentration of endotoxin-free detoxigal-treated Gal 3 (detoxi-Gal 3). LPS contamination of the Gal 3 extract preparation, as measured by Limulus Amebocyte Lysate test (Limulus Amebocyte Lysate assay, La Jolla, CA, USA), was assessed by preincubating Gal 3 (40 μM) and LPS (6.2 mg/Kg) in 0.5 mL of PBS for 30 min before IP administration. Control animals received PBS, Gal 3 only or LPS only. The Ethics Committee on Animal Research of the University of Sao Paulo approved all the procedures performed in the study described here.

Galectin 3 endows low doses of LPS with the ability to activate neutrophils

The effects of Gal 3 on LPS-mediated neutrophil activation were then investigated. LPS is known to lose most of its neutrophil activating efficiency in the absence of serum LPS-binding protein (LBP) and soluble CD14 [24] and concentrations as high as 10 μg/ml of LPS are required to activate neutrophils in the absence of serum (data not shown). When unprimed human neutrophils were incubated with suboptimal E. coli LPS concentration (1 μg/ml) or with 0.4 μM detoxi-Gal 3, separately, these stimuli induced little or no neutrophil activation (Figure 2A). By contrast, a two- to three-fold increase of CD11b expression was observed when neutrophils were treated with the same amount of LPS that had been preincubated with Gal 3 (Figure 2A, 2B). We also tested whether Gal 3 was able to enhance neutrophil oxidative responses to LPS. LPS is not an efficient trigger of the oxidative burst but it is known to prime PMN for an enhanced oxidative response to fMLP [25]. Therefore, we first primed PMN with either Gal 3, LPS or a pre-incubated mixture of Gal 3 and LPS, in the presence of the fluorescent probe DCFHDA, and then further activated PMN with fMLP. The results show that LPS preincubation with Gal 3 increases the oxidant response of PMN to LPS itself (DCFHDA indexes of 2.77±0.2 and 2±0.09 with LPS/Gal3 and LPS alone, respectively) (Figure 2C).
Galectin-3 Potentiates LPS Activity

Figure 2. Gal 3 increases the ability of LPS to activate neutrophils and induces oxidative responses. PMNs (2.0 × 10^6/mL) were incubated for 45 min at 37°C with E. coli LPS (1 µg/mL) and Gal 3 (0.4 µM), which had been preincubated separately or together for 30 min at 37°C after labeling with a specific anti-CD11b mAb, cells were analyzed by flow cytometry. A: Representative histogram of neutrophil CD11b expression. B: Bar graph representation of data obtained from 5 experiments (mean ± SD). C: PMNs were incubated at 37°C for 30 min with DCFHDA and either Gal 3 (5 µg/mL) or a mixture of Gal 3 and LPS pre-incubated for 30 min at 37°C. Then, PMN were further activated or not with fMLP 10^-6 M for 7 minutes. The reaction was stopped by the addition of ice-cold PBS-azide 0.1% and the oxidation-dependent fluorescence of intracellular DCFHDA was measured as described in Methods. The results are given as DCFHDA index, i.e. the mean fluorescence intensity MFI of each sample/MFI of resting PMN (n = 3). *p<0.05, ** p<0.01. doi:10.1371/journal.pone.0026004.g002

Moreover, it potentiates LPS priming effect: PMN preincubation with the LPS/Gal3 mixture lead to up to 3 fold the oxidative response to fMLP, as compared to the 1.8 fold increase observed after priming by LPS alone (Figure 2C).

Finally, the effects of Gal 3 on neutrophil activation were also tested with LPS in the presence of serum factors such as LBP and CD14. In the presence of 0.2% normal human serum, as low as 1 ng/mL of LPS were able to activate neutrophils. Here again, Gal 3 caused a further decrease in the LPS threshold since, in the presence of serum, 0.1 ng/mL LPS preincubated with Gal 3 induced an increase of neutrophil CD11b expression similar to 1 ng/mL LPS alone (Figure 2D).

Galectin-3 effects on LPS-mediated activation require galectin-3/LPS interactions

We initially concluded, as others [26,27], that the effect of Gal 3 on neutrophils required cell priming by LPS. However, surprisingly, the enhancing effect of Gal 3 on LPS-mediated neutrophil activation was not observed when neutrophils were primed with 1 µg/mL of LPS before the addition of Gal 3 (0.2 µM) or vice-versa (Figure 3A). Indeed, LPS- or Gal 3-primed cells did not differ significantly from cells treated with Gal 3 or LPS alone (Figure 3A).

Importantly, Gal 3 effects on neutrophil activation required a prior interaction of Gal 3 with LPS, since only the pre-incubated Gal 3/LPS was able to significantly increase neutrophil activation (Figure 3A). In fact, we observed a dose-dependent up-regulation of CD11b expression with increasing concentrations of LPS/Gal 3 during the preincubation step, although the final concentration in contact with neutrophils was kept constant (0.2 µM Gal 3, 1 µg/mL LPS) (Figure 3B). Moreover, a time-response curve for LPS/Gal 3 preincubulation revealed that the ability of Gal 3 to interact with LPS and to induce CD11b up-regulation of expression was very rapid in onset, reaching a plateau after 10 min of preincubation (Figure 3C). These results further emphasize the importance of a direct interaction of Gal 3 with LPS. The ability of Gal 3 to enhance neutrophil activation was specifically observed with LPS and not upon pre-incubation with other stimuli such as fMLP, TNF-α or IL-8 (Figure 3D).

Galectin-3/LPS-mediated neutrophil activation relies on N- or C-terminal parts of Gal 3, according to LPS bacterial strains

In order to investigate the Gal 3 effects in the observed effects, we analyzed LPS from different strain known to interact either with gal 3 lectin domain (Klebsiella pneumoniae), with gal 3 N-terminal part (Salmonella minnesota 87 [Rd mutant]) or both N-terminal and lectin parts (E. coli) [21,28]. As shown in Figure 3E, Gal 3 endows all three strains of LPS with an enhanced ability to up-regulate neutrophil CD11b (black bars). This effect was inhibited by lactose in the case of E. coli LPS and K. pneumonia, but not in the case of S. minnesota 87 LPS, confirming that the lectin domain is not involved in Gal 3 interaction with this latter LPS. Altogether, these results indicate that Gal 3 effects on LPS-mediated neutrophil activation require an interaction of LPS with either the glycan-binding or the N-terminal part of Gal 3.

Gal-3 strikingly enhances the interaction of LPS with neutrophils

To test whether the Gal 3-mediated increase in LPS binding might be caused by an up-regulation of LPS receptors on neutrophils, we analyzed the expression of CD14 and TLR4. As shown in figure 4, there was no significant change in TLR4 (A) and CD14 (B) expressions after neutrophil stimulation with the Gal 3/LPS complex. We then hypothesized that Gal 3 enhances the effects of LPS by increasing its binding to neutrophil surface. We thus preincubated FITC-labeled E. coli LPS with increasing concentrations of Gal 3 for 30 min before adding it to neutrophils. One should point out that low concentrations of FITC-LPS (1 µg/mL) preincubated with 0.4 µM of Gal 3, in the absence of serum, did not result in a level of fluorescence intensity detected by flow cytometry. Therefore, we increased proportionally the doses of FITC-LPS and Gal 3 and found that the dose of 12.5 µg/mL LPS allowed the detection of cell-bound LPS. Preincubation of this amount of LPS with increasing concentrations of Gal 3 showed a significant increase of LPS binding to neutrophils for a Gal 3/LPS proportion (4 µM Gal 3 per 10 µg LPS) similar to that required for neutrophil activation. As expected, previous treatment of Gal 3 with lactose (12.5 mM) specifically inhibited the Gal 3-induced binding of LPS to neutrophils (Figure 4D). Gal 3/LPS interactions thus strikingly enhance the binding of LPS to the cell surface.

LPS induces N-terminal part-dependent Gal 3 oligomerization

Since the binding of FITC-LPS to neutrophils is more pronounced as the concentration of Gal 3 reaches a threshold concentration (2 µM, Figure 4C), we next tested the ability of LPS to trigger galectin-3 self-association. Biotin-labeled Gal 3, without
Figure 3. Galectin-3 specifically enhances LPS-mediated neutrophil activation and requires a direct interaction with LPS for its effect. A: PMNs were primed for 30 min at 37°C with Gal 3 (0.2 μM) or E. coli LPS (1 μg/mL) and then stimulated with LPS (1 μg/mL) or Gal 3 (0.2 μM), respectively. Alternatively, Gal 3 (1 μM) and LPS (5 μg/mL) were preincubated together for 30 min at 37°C and then diluted to 0.2 μM (Gal 3) and 1 μg/mL (LPS) to be used to stimulate PMNs (n = 3). B: Effect of increasing LPS and Gal 3 concentrations in the pre-incubation mixture. Increasing concentrations of Gal 3 (0.2 μM to 25 μM) and LPS (1 μg/mL to 125 μg/mL) were preincubated together for 30 min at 37°C. They were then diluted in HBSS 2 to the final Gal 3 – 0.2 μM and LPS – 1 μg/ml concentrations and added to PMN for a 45-min incubation at 37°C. C: Time-response curve of Gal 3 and LPS preincubation. Gal 3 (7 μM) and LPS (35 μg/ml) were preincubated together for 0–30 min, as indicated, at 37°C and then diluted to 0.2 μM (Gal 3) and 1 μg/mL (LPS) to be used to stimulate PMNs for a 45-min incubation at 37°C (representative from 2 independent experiments). D: PMNs were stimulated with LPS (1 μg/ml), fMLP (10^{-6} M), TNF-α (10 ng/ml) or IL-8 (25 ng/ml), which had all been preincubated without (black) or with Gal 3 (0.4 μM, grey) for 30 min at 37°C. Neutrophil CD11b expression was measured as in figure 1 (n = 5). E: Gal 3 effect on neutrophil activation by LPS from various strains of bacteria. Gal 3 (1 μM) was preincubated with 10 μg/ml LPS from E. coli, K. pneumonia or S. minnesota R7 for 30 min at 37°C, in presence or absence of 10 mM lactose (lac). Then, each mixture was diluted to 0.2 μM (Gal 3) and 1 μg/ml (LPS) concentrations and used to stimulate PMNs (2x10^6/mL) for 45 min at 37°C, and analyzed for CD11b expression as above. Results are expressed as mean fluorescence intensity (MFI) (n = 3). * p<0.05, **p<0.01, ***p<0.001.

doi:10.1371/journal.pone.0026004.g003

or with LPS, was allowed to interact with a galectin-3-coated plate, in the presence of increasing amounts of unlabeled Gal 3. As shown in figure 5A, the unlabeled Gal 3 did not compete with the biotin-galectin-3, since the amount of biotin-galectin 3 binding was not decreased, but on the contrary slightly enhanced in the presence of a 10 time excess of unlabeled Gal 3. This suggests the occurrence of Gal 3 oligomerization, which was enhanced in the presence of LPS (Figure 5A).

In order to test the hypothesis that LPS induces Gal 3 oligomerization via the N-terminal part of the molecule, we used the C-terminal fragment Gal 3C, generated by collagenase digestion of Gal 3, which lacks the N-terminal part but still possesses the carbohydrate-binding activity. First, Gal 3C was shown to be able to bind to neutrophils, as detected with a polyclonal anti-Gal 3C antibody (Figure 5B). This binding was saturable, reaching a plateau at about 1.2 μM Gal 3C, unlike that observed with FITC-labeled full-length Gal 3 (Figure 5C). This non-saturable binding illustrates the ability of the full-length Gal 3, at high concentration, to form multimers, via its N-terminal part, on neutrophils, while Gal 3C had lost this ability. Similarly, contrasting with the full-length Gal 3, Gal 3C was unable to increase the binding of FITC-LPS to neutrophils (Figure 5D) and to enhance the LPS-mediated neutrophil activation, as shown in Figure 5E, where LPS was preincubated with Gal 3C concentrations up to four times greater than those used for full-length Gal 3. These results emphasize the importance of N-terminal part-mediated Gal 3 oligomerization in its ability to enhance LPS binding to and activation of neutrophils.

Gal 3/LPS interaction leads to an increase in the fluorescence of FITC-LPS in a similar way as serum LBP protein

The fact that Gal 3/LPS interaction induces greater-than-20-fold increase in FITC-LPS binding to neutrophils but only a three-fold increase in LPS-mediated CD11b up-regulation raised the possibility that galectin-3 might interfere with the intramolecular self-quenching of fluorescein. It has long been known that the fluorescence of FITC-LPS aggregates is self quenched but should increase when the aggregates dissociate [29] or the spacing between FITC-LPS molecules within aggregates increase [30], because of dequenching. Therefore, FITC-LPS, preincubated or not with Gal 3 or with serum LPB, was analyzed by gel filtration followed by fluorescence detection. Figure 6 represents the analysis of the main peak of FITC-LPS recovered in the void volume and clearly demonstrates that the presence of Gal 3 enhances three times the FITC-LPS fluorescence. Similar results were obtained...
when FITC-LPS was preincubated with serum LBP, which it is known to promote LPS disaggregation [31]. This result suggests that Gal 3/LPS interaction is able to modify the LPS aggregate structure, which may account, at least in part, for its potentiating effect on LPS-induced neutrophil activation.

Exogenous Gal 3 increases mortality to endotoxin shock induced by LPS

Endotoxic shock is the most severe form of LPS-mediated inflammatory disease, which is mainly mediated by an uncontrolled neutrophil activation [32–36]. So far we have shown that Gal 3 lowers the activation threshold of LPS-stimulated neutrophils in vitro. We, thus, further explored Gal 3 effect in an in vivo sepsis model. First, in order to determine a suitable concentration of LPS for inducing endotoxemia, mice were challenged with different doses of LPS (Figure 7A). All mice receiving 25 mg/Kg LPS died, while those receiving LPS at 6.2 mg/Kg exhibited 50% survival during a 30-hour period. Therefore, we assessed the influence of Gal 3 on endotoxin-mediated mortality by measuring survival of mice challenged with LPS [6.2 mg/Kg] preincubated with 500 µL of Gal 3 (40 µM) for 15 minutes before the challenge. As shown in figure 7B, all mice receiving PBS or Gal 3 alone survived, while 60% of mice receiving LPS at 6.2 mg/Kg survived up to 30 h past challenge, as expected. Interestingly, all mice challenged with LPS pre-incubated with Gal 3 died within 30 h after challenge. This result suggests that exogenous Gal 3 can enhance the effect of LPS both in vitro and in vivo.

Discussion

The major conclusion of this study is that galectin-3 decreases ten times the LPS concentration threshold for neutrophil activation. This may be important in inflammation sites where Gal 3, secreted in situ by macrophages or mast cells, may render neutrophils particularly sensitive to LPS.

Various reports have described Gal 3 in vitro pro-inflammatory effects on neutrophils, which required cell priming with fMLP [17] or TNF-α [37]. Similarly, Almkvist and colleagues previously stated that neutrophils had to encounter bacterial LPS first, in order to be activated by galectin-3, on the basis of results showing that Gal 3 triggered responses of neutrophils preincubated with 10 µg/ml LPS [27]. In our experimental settings, which used LPS concentrations as low as 1 µg/ml in the absence of serum or 1 ng/ml with serum, Gal 3 had no effect on LPS-pretreated neutrophils. However, Gal 3 pre-incubation with LPS enhanced the ability of these low LPS concentrations to activate naïve, unprimed neutrophils, as shown by the upregulation of CD11b expression. Gal 3 specifically potentiated neutrophil activation by LPS and had no effect on cell activation by other agonists such as fMLP, TNF-α or IL-8. Indeed, our results emphasize the importance of specific Gal 3/LPS interactions, as shown by a concentration dependent effect of Gal 3/LPS pre-incubation step on the resulting neutrophil activation (Figure 3B). The required concentrations for the galectin 3/LPS pre-incubation step are high but are most probably reached when Gal 3 secreting macrophages get in contact with LPS-releasing bacteria in inflamed tissues. Moreover, the final Gal 3 concentrations used to stimulate neutrophils were similar or lower to those used in previously reported in vitro data on Gal 3 effects [16,17,19,20,26,27].

Our results confirm that some of the in vitro effects of recombinant E. coli-derived Gal 3 preparations are due to an LPS contamination and are inhibited by polymyxin B [38]. The detoxified LPS-free Gal 3 efficiently bound to neutrophils, via its...
carbohydrate recognition domain but had no significant effect on neutrophils at concentrations lower than 0.8 μM. Two independent LPS binding sites on galectin-3 have been demonstrated so far. One is the carbohydrate binding site in the C-terminal domain of Galectin-3, which confers binding to β-galactoside-containing LPS from K. pneumonia. In contrast, S. minnesota LPS is devoid of β-galactosides, but can bind to a site within the N-terminal domain of galectin-3 through its Lipid A part, known to be essential for LPS-mediated bioactivity [28]. In addition, E. coli LPS binds to galectin-3 both through Lipid A and β-galactoside-containing polysaccharide chains [21]. The analysis of LPS from different strains of bacteria showed that Gal 3 interaction with E. coli, K. pneumonia, and S. minnesota LPS enhanced LPS-mediated neutrophil activation. Accordingly, blocking the lectin domain with lactose inhibited the effect of Gal 3 on E. coli and K. pneumonia LPS but not its effect on S. minnesota LPS, further demonstrating that, no matter what domain is involved, the interaction between LPS and Gal 3 is essential to the enhanced neutrophil activation mediated by LPS.

The effect of Gal 3 was further investigated with Gal 3 C-terminal fragment Gal 3C, which retains its ability to bind, via its lectin site, to neutrophil membrane (Figure 5B). Although this carbohydrate recognition domain but had no significant effect on neutrophils at concentrations lower than 0.8 μM.

Two independent LPS binding sites on galectin-3 have been demonstrated so far. One is the carbohydrate binding site in the C-terminal domain of Galectin-3, which confers binding to β-galactoside-containing LPS from K. pneumonia. In contrast, S. minnesota LPS is devoid of β-galactosides, but can bind to a site within the N-terminal domain of galectin-3 through its Lipid A part, known to be essential for LPS-mediated bioactivity [28]. In addition, E. coli LPS binds to galectin-3 both through Lipid A and β-galactoside-containing polysaccharide chains [21]. The analysis of LPS from different strains of bacteria showed that Gal 3 interaction with E. coli, K. pneumonia, and S. minnesota LPS enhanced LPS-mediated neutrophil activation. Accordingly, blocking the lectin domain with lactose inhibited the effect of Gal 3 on E. coli and K. pneumonia LPS but not its effect on S. minnesota LPS, further demonstrating that, no matter what domain is involved, the interaction between LPS and Gal 3 is essential to the enhanced neutrophil activation mediated by LPS.

The effect of Gal 3 was further investigated with Gal 3 C-terminal fragment Gal 3C, which retains its ability to bind, via its lectin site, to neutrophil membrane (Figure 5B). Although this carbohydrate recognition domain but had no significant effect on neutrophils at concentrations lower than 0.8 μM.

Two independent LPS binding sites on galectin-3 have been demonstrated so far. One is the carbohydrate binding site in the C-terminal domain of Galectin-3, which confers binding to β-galactoside-containing LPS from K. pneumonia. In contrast, S. minnesota LPS is devoid of β-galactosides, but can bind to a site within the N-terminal domain of galectin-3 through its Lipid A part, known to be essential for LPS-mediated bioactivity [28]. In addition, E. coli LPS binds to galectin-3 both through Lipid A and β-galactoside-containing polysaccharide chains [21]. The analysis of LPS from different strains of bacteria showed that Gal 3 interaction with E. coli, K. pneumonia, and S. minnesota LPS enhanced LPS-mediated neutrophil activation. Accordingly, blocking the lectin domain with lactose inhibited the effect of Gal 3 on E. coli and K. pneumonia LPS but not its effect on S. minnesota LPS, further demonstrating that, no matter what domain is involved, the interaction between LPS and Gal 3 is essential to the enhanced neutrophil activation mediated by LPS.

The effect of Gal 3 was further investigated with Gal 3 C-terminal fragment Gal 3C, which retains its ability to bind, via its lectin site, to neutrophil membrane (Figure 5B). Although this carbohydrate recognition domain but had no significant effect on neutrophils at concentrations lower than 0.8 μM.

Two independent LPS binding sites on galectin-3 have been demonstrated so far. One is the carbohydrate binding site in the C-terminal domain of Galectin-3, which confers binding to β-galactoside-containing LPS from K. pneumonia. In contrast, S. minnesota LPS is devoid of β-galactosides, but can bind to a site within the N-terminal domain of galectin-3 through its Lipid A part, known to be essential for LPS-mediated bioactivity [28]. In addition, E. coli LPS binds to galectin-3 both through Lipid A and β-galactoside-containing polysaccharide chains [21]. The analysis of LPS from different strains of bacteria showed that Gal 3 interaction with E. coli, K. pneumonia, and S. minnesota LPS enhanced LPS-mediated neutrophil activation. Accordingly, blocking the lectin domain with lactose inhibited the effect of Gal 3 on E. coli and K. pneumonia LPS but not its effect on S. minnesota LPS, further demonstrating that, no matter what domain is involved, the interaction between LPS and Gal 3 is essential to the enhanced neutrophil activation mediated by LPS.

The effect of Gal 3 was further investigated with Gal 3 C-terminal fragment Gal 3C, which retains its ability to bind, via its lectin site, to neutrophil membrane (Figure 5B). Although this carbohydrate recognition domain but had no significant effect on neutrophils at concentrations lower than 0.8 μM. Two independent LPS binding sites on galectin-3 have been demonstrated so far. One is the carbohydrate binding site in the C-terminal domain of Galectin-3, which confers binding to β-galactoside-containing LPS from K. pneumonia. In contrast, S. minnesota LPS is devoid of β-galactosides, but can bind to a site within the N-terminal domain of galectin-3 through its Lipid A part, known to be essential for LPS-mediated bioactivity [28]. In addition, E. coli LPS binds to galectin-3 both through Lipid A and β-galactoside-containing polysaccharide chains [21]. The analysis of LPS from different strains of bacteria showed that Gal 3 interaction with E. coli, K. pneumonia, and S. minnesota LPS enhanced LPS-mediated neutrophil activation. Accordingly, blocking the lectin domain with lactose inhibited the effect of Gal 3 on E. coli and K. pneumonia LPS but not its effect on S. minnesota LPS, further demonstrating that, no matter what domain is involved, the interaction between LPS and Gal 3 is essential to the enhanced neutrophil activation mediated by LPS.

The effect of Gal 3 was further investigated with Gal 3 C-terminal fragment Gal 3C, which retains its ability to bind, via its lectin site, to neutrophil membrane (Figure 5B). Although this carbohydrate recognition domain but had no significant effect on neutrophils at concentrations lower than 0.8 μM.

Two independent LPS binding sites on galectin-3 have been demonstrated so far. One is the carbohydrate binding site in the C-terminal domain of Galectin-3, which confers binding to β-galactoside-containing LPS from K. pneumonia. In contrast, S. minnesota LPS is devoid of β-galactosides, but can bind to a site within the N-terminal domain of galectin-3 through its Lipid A part, known to be essential for LPS-mediated bioactivity [28]. In addition, E. coli LPS binds to galectin-3 both through Lipid A and β-galactoside-containing polysaccharide chains [21]. The analysis of LPS from different strains of bacteria showed that Gal 3 interaction with E. coli, K. pneumonia, and S. minnesota LPS enhanced LPS-mediated neutrophil activation. Accordingly, blocking the lectin domain with lactose inhibited the effect of Gal 3 on E. coli and K. pneumonia LPS but not its effect on S. minnesota LPS, further demonstrating that, no matter what domain is involved, the interaction between LPS and Gal 3 is essential to the enhanced neutrophil activation mediated by LPS.

The effect of Gal 3 was further investigated with Gal 3 C-terminal fragment Gal 3C, which retains its ability to bind, via its lectin site, to neutrophil membrane (Figure 5B). Although this carbohydrate recognition domain but had no significant effect on neutrophils at concentrations lower than 0.8 μM.

Two independent LPS binding sites on galectin-3 have been demonstrated so far. One is the carbohydrate binding site in the C-terminal domain of Galectin-3, which confers binding to β-galactoside-containing LPS from K. pneumonia. In contrast, S. minnesota LPS is devoid of β-galactosides, but can bind to a site within the N-terminal domain of galectin-3 through its Lipid A part, known to be essential for LPS-mediated bioactivity [28]. In addition, E. coli LPS binds to galectin-3 both through Lipid A and β-galactoside-containing polysaccharide chains [21]. The analysis of LPS from different strains of bacteria showed that Gal 3 interaction with E. coli, K. pneumonia, and S. minnesota LPS enhanced LPS-mediated neutrophil activation. Accordingly, blocking the lectin domain with lactose inhibited the effect of Gal 3 on E. coli and K. pneumonia LPS but not its effect on S. minnesota LPS, further demonstrating that, no matter what domain is involved, the interaction between LPS and Gal 3 is essential to the enhanced neutrophil activation mediated by LPS.

The effect of Gal 3 was further investigated with Gal 3 C-terminal fragment Gal 3C, which retains its ability to bind, via its lectin site, to neutrophil membrane (Figure 5B). Although this carbohydrate recognition domain but had no significant effect on neutrophils at concentrations lower than 0.8 μM. Two independent LPS binding sites on galectin-3 have been demonstrated so far. One is the carbohydrate binding site in the C-terminal domain of Galectin-3, which confers binding to β-galactoside-containing LPS from K. pneumonia. In contrast, S. minnesota LPS is devoid of β-galactosides, but can bind to a site within the N-terminal domain of galectin-3 through its Lipid A part, known to be essential for LPS-mediated bioactivity [28]. In addition, E. coli LPS binds to galectin-3 both through Lipid A and β-galactoside-containing polysaccharide chains [21]. The analysis of LPS from different strains of bacteria showed that Gal 3 interaction with E. coli, K. pneumonia, and S. minnesota LPS enhanced LPS-mediated neutrophil activation. Accordingly, blocking the lectin domain with lactose inhibited the effect of Gal 3 on E. coli and K. pneumonia LPS but not its effect on S. minnesota LPS, further demonstrating that, no matter what domain is involved, the interaction between LPS and Gal 3 is essential to the enhanced neutrophil activation mediated by LPS.

The effect of Gal 3 was further investigated with Gal 3 C-terminal fragment Gal 3C, which retains its ability to bind, via its lectin site, to neutrophil membrane (Figure 5B). Although this carbohydrate recognition domain but had no significant effect on neutrophils at concentrations lower than 0.8 μM.
truncated Gal 3 is able to bind E. coli LPS, it had lost its ability to enhance the binding of LPS to neutrophils (Figure 5D) and the resulting cell activation (Figure 5E). These results emphasize the importance of Gal 3 oligomerization, via its N-terminal part, in the LPS-enhancing effect.

Gal 3 oligomerization could also account for the striking increase of LPS binding to neutrophils, when LPS was preincubated with Gal 3, in spite of a constant number of LPS receptors, TLR4 and CD14.

It is well established that, in the absence of ligands, galectin-3 is monomeric, but it oligomerizes upon binding to synthetic multivalent or cell surface glycans, through self-association of N-terminal parts [8,22,39]. Efficient oligomerization, in the presence of ligands such as IgE, was shown to require a minimal galectin-3 concentration of 1.0 μM [22]. Similarly, galectin-3 oligomerization was reported to occur on the surface of neutrophils [18] but with 2 μM Gal 3 concentration, i.e. 10 times that of our experimental setting, which is probably not sufficient to allow the formation of oligomers on the cell surface. The fact that the enhancement of LPS-mediated neutrophil activation was only achieved if galectin-3 had been preincubated, at concentrations equal or higher than 1 μM, with LPS, strongly suggests that LPS itself induces galectin-3 oligomerization during this preincubation step. This was confirmed by the analysis of the formation of galectin 3 oligomers on galectin 3-coated plates, which was significantly enhanced by the presence of LPS (Figure 5A). To our knowledge, this is the first observation of galectin-3 oligomerization promoted by LPS.

Our results raise the question as to how galectin-3 oligomerization could lower the activation threshold of neutrophils to LPS. One possibility is that each galectin-3 oligomer, binding several LPS molecules, cross-links LPS receptors such as CD14 and TLR4 on the cell surface, thereby increasing their cell activating efficiency, as schematized in figure 8. Moreover, simultaneous interaction of galectin-3 carbohydrate recognition domain with glycans on LPS receptors such as CD14 [31,40,41] could further enhance the binding of LPS to the cell surface. Another hypothesis, which does not exclude the former one, is that galectin 3 dissociates LPS aggregates, as has been observed with LPS-binding protein (LBP). Indeed, LPS, in aqueous suspension, forms aggregates with low cell activating efficiency, which are disrupted by LPS-binding protein (LBP) [42]. This accelerates LPS binding to CD14 and enhances the resulting TLR-4-mediated cell signaling. We observed that the fluorescence of FITC-LPS was enhanced upon incubation with Galectin 3 (Figure 6), which indicates that galectin-3 somehow interferes with LPS aggregate structure. However, at this point we are not able to assert that Gal 3 promotes LPS disaggregation in a way similar to LBP or that it just interferes with the space between FITC molecules, thus promoting dequenching [30].

When LPS reaches the systemic circulation, it induces a massive release of proinflammatory cytokines, that cause the pathophysiological state known as endotoxic shock [43]. Our results showing an increased mortality of mice challenged with LPS preincubated with galectin-3 do not prove that the increased mortality is due to the direct activation of neutrophils by LPS/Gal3 complexes. It could be due to LPS/Gal3 interactions with resident cells such as macrophages, resulting in increased secretion of TNF-α, IL-8 and other cytokines and ultimately in neutrophil hyperactivation. These results, however, definitely argue in favour of an amplifying role for galectin-3 in LPS-induced cellular responses. This contrasts with the data of Li and colleagues [21], who demonstrated that gal3−/− mice were more susceptible to endotoxin shock and observed dramatically increased galectin-3 serum levels in wild-type mice 4 h after LPS challenge. The reason for this discrepancy may be searched in the analogy between Gal 3 and LBP behavior towards LPS. Indeed, in spite of the enhancing effect of LBP on LPS signalling at low concentration, LBP inhibits this signalling, when present in high concentration, by shuttling LPS to the serum lipoproteins and by formation of LPS aggregates [44,45]. It has, therefore, been suggested that LBP may serve as an inhibitor of the excessive response to LPS, which would explain its higher levels found in the serum of septic patients [46]. It is tempting to speculate that, in the experimental setting used by Li and colleagues [21], the systemic galectin-3 concentration found after LPS challenge (~300 ng/mL) would not be sufficient to enhance LPS-induced activation and therefore may exert an inhibitory role. The same authors showed that the in vitro preincubation of LPS with galectin-3 reduced the responsiveness of bone marrow-derived macrophages (BMMDs) to LPS. However, BMMDs may react differently than neutrophils and, more importantly, they used galectin-3 doses as low as 5–20 nM, which, in our system, would be without enhancing effect.

In conclusion, regarding the physiological function played by LPS-galectin-3 interactions during infections caused by gram-negative bacteria, we propose that galectin-3 could serve as a sensor to detect small amounts of LPS and allow it to efficiently
activate recruited neutrophils. Of note, our recent observation that galectin-3-deficient mice (gal3<sup>-/-</sup>) developed a delayed inflammatory response during the early phase (6–24 hrs) of <em>Rhodococcus equi</em> infection [47] argues in favour of a role for galectin-3 as a pathogen danger signal in this model. Moreover, galectin-3 could be an innate immune sensor with a broader specificity than LPS. Indeed, galectin-3 has been shown to bind mycolic acid (MA), the major constituents of Mycobacterium tuberculosis cell envelop [48]. Interestingly, these authors also demonstrated that MA interferes with an initial formation of galectin-3 oligomers on a laminin substratum, although galectin-3 oligomerization on immunobilized MA was not assayed. The ability of galectin-3 to bind two hydrophobic ligands such as MA and Lipid A, as in <em>Salmonella minnesota</em> R7 LPS, opens the possibility that galectin-3 may also interact with Lipoteichoic acid (LTA), a major constituent of the wall cell of gram-positive bacteria. Interestingly, LPS-binding protein also interacts with LTA from gram-positive bacteria and promotes its interaction with CD14 [49]. The possible interaction between galectin-3 and LTA, or other product from gram-positive bacteria, warrants further investigation.

**Acknowledgments**

We are grateful to Catherine Fitting (Institut Pasteur, Paris), who generously provided LPS from <em>Salmonella minnesota</em> R7 (Rd), which had been produced by Sigma but was no longer commercially available. Many thanks to Philippe Lesave, Roger Chamas and Marcelo Dias Baruffi for helpful discussions. We also thank Sylvain Bigot for excellent technical assistance and Thiago Aparecido da Silva and Rafael Ricci de Azevedo for helping in gel filtration and ROS experiments, respectively. The authors also acknowledge Marise L. Fermino, Cláudia D. Polli and Karina A. Toledo.

**Author Contributions**

Conceived and designed the experiments: MLF ESB LHM. Performed the experiments: MLF CDP KAT. Analyzed the data: MLF CDP GPS ESB LHM. Contributed reagents/materials/analysis tools: FTL DKH MCRAB ESB LHM. Wrote the paper: MLF ESB LHM.

**References**

1. Raetz CR, Ulevitch RJ, Wright SD, Sibley CH, Ding A, et al. (1991) Gram-negative endotoxin: an extraordinary lipid with profound effects on eukaryotic signal transduction. FASEB J 5: 2652–2660.
2. Ulevitch RJ, Tobias PS (1995) Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Annu Rev Immunol 13: 437–457.
3. Remer KA, Brcic M, Jungi TW (2003) Toll-like receptor-4 is involved in eliciting an LPS-induced oxidative burst in neutrophils. Immunol Lett 85: 75–80.
4. Liew AW, Wu Y, Yan H, Yang M (2005) Effective statistical features for coding and non-coding DNA sequence classification for yeast, <em>C. elegans</em> and human. Int J Bioinform Res Appl 1: 181–201.
5. Liu FT (2002) Galectins: novel anti-inflammatory drug targets. Expert Opin Ther Targets 6: 461–468.
6. Rabinovich GA, Baum LG, Tinaro N, Paganelli R, Natoli C, et al. (2002) Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response? Trends Immunol 23: 313–320.
7. Yang RY, Liu FT (2003) Galectins in cell growth and apoptosis. Cell Mol Life Sci 60: 267–276.
8. Ahmad N, Gabius HJ, Andre S, Kalner H, Sabesan S, et al. (2004) Galectin-3 precipitates as a pentamer with synthetic multivalent carbohydrates and forms heterogeneous cross-linked complexes. J Biol Chem 279: 10841–10847.
9. Brewer FC (2002) Binding and cross-linking properties of galectins. Biochem Biophys Acta 1572: 253–267.
10. Ho MK, Springer TA (1982) Mac-1 antigen: quantitative expression in macrophage populations and tissues, and immunofluorescent localization in spleen. J Immunol 128: 2281–2286.
11. Liu FT (2005) Regulatory roles of galectins in the immune response. Int Arch Allergy Immunol 136: 385–400.
12. Farnworth SL, Henderson NC, Mackinnon AC, Atkinson KM, Wilkinson T, et al. (2008) Galectin-3 reduces the severity of <em>Pneumococcal pneumonia</em> by augmenting neutrophil function. Am J Pathol 172: 395–405.

Figure 8. Schematic view of putative mechanisms responsible for galectin-3 enhancement of LPS-induced neutrophil activation. Monomeric Galectin-3 interacts with LPS glycans from LPS aggregates via its C-terminal domain. LPS/Gal3 interactions induce Gal3 oligomerization, which promotes the dissolution of LPS aggregates, stabilizes LPS monomers and enhances the LPS interaction with surface receptors, leading to increased neutrophil activation. CD14 only is shown as the initial LPS ligand on neutrophils, because it is highly glycosylated and could, potentially, interact directly with Gal3. Moreover, being GPI-anchored, CD14 would be most easily clustered on the cell surface. However, this implies a secondary clustering of TLR/MD2, which would transmit or modulate signals into the cell.

doi:10.1371/journal.pone.0026004.g008
13. Hsu DK, Yang RA, Pan Z, Yu L, Solonon DR, et al. (2000) Targeted disruption of the galectin-3 gene results in attenuated peritoneal inflammatory responses. Am J Pathol 156: 1073–1083.

14. Nieminen J, Se-Perier C, Bhauask P, Poier F, Sato S (2008) Role of galectin-3 in leukocyte recruitment in a murine model of lung infection by *Streptococcus pneumoniae*. J Immunol 180: 2466–2473.

15. Sato S, Ouellet N, Pelletier I, Simard M, Rancourt A, et al. (2002) Role of galectin-3 as an adhesion molecule for neutrophil extravasation during streptococcal pneumonia. J Immunol 168: 1011–1022.

16. Fernández GC, Barregui JM, Rulfi C, Toscano MA, Gómez SA, et al. (2005) Galectin-3 and soluble fibrinogen in concert to modulate neutrophil activation and survival: involvement of alternative MAPK pathways. Glycobiology 15: 519–527.

17. Karlsson A, Follin P, Leffler H, Dahlgren C (1998) Galectin-3 activates the NADPH-oxidase in exudated but not peripheral blood neutrophils. Blood 91: 3430–3438.

18. Nieminen J, Kuno A, Hirabayashi J, Sato S (2005) Visualization of galectin-3 oligomerization on the surface of neutrophils and endothelial cells using fluorescence resonance energy transfer. J Biol Chem 280: 1374–1383.

19. Nieminen J, Se-Perier C, Sato S (2005) Galectin-3 interacts with naive and primed neutrophils, inducing innate immune responses. J Leukoc Biol 78: 1127–1135. Erratum in: J Leukoc Biol 83: 797.

20. Yamaoka A, Kusahara I, Frigeri LG, Liu FT (1995) A human lectin, galectin-3 (epilun bp/Mai-2), stimulates superoxide production by neutrophils. J Immunol 154: 5479–5487.

21. Li Y, Komai Koma M, Gilchrist DS, Hsu DK, Liu FT, et al. (2008) Galectin-3 is a negative regulator of lipopolysaccharide-mediated inflammation. J Immunol 181: 2701–2709.

22. Hsu DK, Zuberi RI, Liu FT (1992) Biochemical and biophysical characterization of human recombinant IgE-binding protein, an S-type animal lectin. J Biol Chem 267: 14167–14174.

23. Feizi T, Solomon JC, Yuen GT, Jong KC, Frigeri LG, et al. (1994) The adhesive specificity of the soluble human lectin, IgE-binding protein, toward lipid-linked oligosaccharides. Presence of the blood group A, B, B-like, and H monosaccharides confers a binding activity to tetrasaccharide (lacto-N-tetraose and lacto-N-neotetraose) backbones. Biochemistry 33: 6342–6349.

24. Workin GS, Avdi N, Vukajlovich S, Tobias PS (1992) Neutrophil adherence induced by lipopolysaccharide as *in vivo*. Role of plasma component interaction with lipopolysaccharide. J Clin Invest 90: 2526–2535.

25. Yee J, Christou NV (1993) Neutrophil priming by lipopolysaccharide involves heterogeneity in calcium-mediated signal transduction. Studies using fluos-3 and flow cytometry. J Immunol 150: 1968–1997.

26. Ahnkist J, Dahlgren C, Leffler H, Karlsson A (2004) Newcastle disease virus neuraminidase primes neutrophils for stimulation by galectin-3 and formyl-Met-Leu-Phe. Exp Cell Res 298: 74–82.

27. Ahnkist J, Faldt J, Dahlgren C, Leffler H, Karlsson A (2001) Lipopolysaccharide-induced gelatinase granule mobilization primes neutrophils for activation by galectin-3 and formylmethionyl-Leu-Phe. Infect Immun 69: 832–837.

28. Mey A, Leffler H, Hnamza N, Normier G, Revillard JP (1996) The animal lecine galectin-3 interacts with bacterial lipopolysaccharides via two independent sites. J Immunol 156: 1572–1577.

29. de Haas CJ, van Leeuwen HJ, Verboof J, van Kessel KP, van Strijp JA (2000) Analysis of lipopolysaccharide (LPS)-binding characteristics of serum components using gel filtration of FITC-labeled LPS. J Immunol Methods 242: 79–89.

30. Tobias PS, Soldau K, Iovine NM, Elsbach P, Weiss J (1997) Lipopolysaccharide (LPS)-binding proteins BPI and LBP form different types of complexes with LPS. J Biol Chem 272: 10862–10865.

31. Tobias PS, Soldau K, Gregor JA, Mintz D, Ulevitch RJ (1995) Lipopolysaccharide binding protein-mediated complexation of lipopolysaccharide with soluble CD14. J Biol Chem 270: 10482.

32. Jaeschke H, Farhood A, Smith CW (1998) Neutrophils contribute to ischemia/reperfusion injury in rat hind limb. FASEB J 14: 3335–3339.

33. Jaeschke H, Farhood A, Smith CW (1991) Neutrophil-induced liver cell injury in endotoxic shock is a CD11b/CD18-dependent mechanism. Am J Physiol 26: G1051–G1056.

34. Mulligan MS, Wilson GP, Todd RF, Smith CW, Anderson DC, et al. (1993) Role of beta 2 integrins and ICAM-1 in lung injury after preparation of multifunctional galectins. Biochem Biophys Res Commun 379: 155–159.

35. Mulligan MS, Wilson GP, Todd RF, Smith CW, Anderson DC, et al. (1993) Role of beta 2 integrins and ICAM-1 in lung injury following ischemia-reperfusion of rat hind limbs. Am J Pathol 143: 464–472.

36. Salomonsson E, Carlsson MC, Ola V, Hendus-Altenburger R, Kahl-Knutson B, et al. (2010) Mutational tuning of galectin-3 specificity and biological function. J Biol Chem 285: 55079–55081.

37. Suzuki K, Andrie S, Kaltner H, Lensch M, Schulze C, et al. (2009) Detection and chromatographic removal of lipopolysaccharide in preparations of multifunctional galectins. Biochem Biophys Res Commun 379: 155–159.

38. Bingle K, Sercarz EE (1994) The specific binding of Lipopolysaccharide (LPS)-binding protein in neutralization of LPS to CD14. J Exp Med 179: 269–277.

39. Yu B, Wright SD (1996) Core A properties of lipopolysaccharide (LPS) binding protein (LBP). I. Transfer of LPS to soluble CD14. J Biol Chem 271: 4100–4107.

40. Jerala R (2007) Structural biology of the LPS recognition. Int J Med Microbiol 297: 533–63.

41. Hallman E, Lichenstein HS, Wurfel MM, Miller DS, Johnson DA, et al. (1994) Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14. J Exp Med 181: 2781–2789.

42. Mulligan MS, Smith CW, Anderson DC, Todd RF, 3rd, Miyasaka M, et al. (1993) Role of beta 2 integrins and ICAM-1 in lung injury after preparation of multifunctional galectins. Biochem Biophys Res Commun 15: 519–527.

43. O’Brien JM, Jr., Ali NA, Aberegg SK, Abraham E (2007) Sepsis. Am J Med 120: 1012–1022.

44. Gutsmann T, Muller M, Carroll SF, MacKenzie RC, Wise A, et al. (2001) Dual role of lipopolysaccharide (LPS)-binding protein in neutralization of LPS and enhancement of LPS-induced activation of mononuclear cells. Infect Immun 69: 6942–6950.

45. Wurfel MM, Hallman E, Wright SD (1995) Soluble CD14 acts as a shuttle in the neutralization of lipopolysaccharide (LPS) by LPS-binding protein and reconstituted high density lipoprotein. J Exp Med 181: 1743–1754.

46. Villar J, Perez-Mendez L, Espinosa E, Flores C, Blanco J, et al. (2009) Serum lipopolysaccharide binding protein levels predict severity of lung injury and mortality in patients with severe sepsis. PLoS One 4: e6818.

47. Ferraz LC, Bernardes ES, Oliveira AF, Ruas LP, Fermino ML, et al. (2008) Serum lipopolysaccharide binding protein levels predict severity of lung injury and mortality in patients with severe sepsis. PLoS One 4: e6818.

48. Barbieri A, schools F, Fiori A (2003) The binding of mycolic acids to galectin-3: a novel interaction between a host soluble lectin and trafficking mycobacterial lipids. FEBS Lett 579: 6749–6755.

49. Schroder NW, Morath S, Alexander C, Hamann L, Hartung T, et al. (2003) Lipoteichoic acid (LTA) of *Streptococcus pneumoniae* and *Staphylococcus aureus* activates immune cells via Toll-like receptor (TLR)-2, lipopolysaccharide-binding protein (LBP), and CD14, whereas TLR-4 and MD-2 are not involved. J Biol Chem 278: 15587–15594.